The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic

Dementia and Geriatric Cognitive Disorders

Volumn 22, Issue 5-6, 2006, Pages 379-384

  Hanyu, Haruo ^a   Shimizu, Soichiro ^a   Hirao, Kentaro ^a   Sakurai, Hirofumi ^a   Iwamoto, Toshihiko ^a   Chikamori, Taishiro ^a   Hida, Satoshi ^a   Yamashina, Akira ^a   Koizumi, Kiyoshi ^a   Abe, Kimihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

123I metaiodobenzylguanidine; Alzheimer's disease; Dementia with Lewy bodies; Parkinson's disease with dementia

Indexed keywords

METAIODOBENZYLGUANIDINE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DRUG UPTAKE; FEMALE; FRONTOTEMPORAL DEMENTIA; HEART; HEART SCINTISCANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEART MUSCLE; HOSPITALIZATION; MEMORY DISORDER; METABOLISM; METHODOLOGY; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; BRAIN; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MEMORY DISORDERS; MYOCARDIUM; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TESTS; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 33750901138     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095641     Document Type: Article

References (37)

1. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawler B, Lippa C, Lopez OL, Machado JC, O'Brien J, Playfer J, Reid W: Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.
2. 123I- metaiodobenzyl guanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-194.
3. Taki J, Nakajima K, Hwang E-H, Matsunari I, Komai K, Yoshita M, et al: Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000;27:566-573.
4. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999;53:1020-1025.
5. Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, Rascol O, Senard JM: Cardiac MIBG scintigraphy is a sensitive tool for detecting cardaiac sympathetic denervation in Parkinson's disease. Mov Disord 2003;18:890-897.
6. 123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001;71:583-588.
7. 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:781-783.
8. 123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med 2003;42:686-690.
9. 123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2006;33:248-253.
10. Yoshita M: Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodobenzyl-guanidine myocardial scintigraphy. J Neurol Sci 1998; 155:60-67.
11. Takatsu H, Nishida H, Satomi K: Differentiation of Parkinson's disease from multiple system atrophy measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000;284:44-45.
12. Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuwert T, Neundorfer B: Differentiation of Parkinson's disease and multiple system atrophy in early disease by means of I-123-MIBG-SPECT. J Neurol Sci 2000;175:3-12.
13. Reinhardt MJ, Jungling FD, Krause TM, Braune S: Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 2000;27:595-600.
14. 123I]MIBG myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. Intern Med 2003;42:127-128.
15. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
16. Solanski KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, britton KE: A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-521.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
18. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byren EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de Vos RAI, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
19. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993;43:250-260.
20. Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
21. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tuchiya K, Mori F, Wakabayashi K, Takahashi H: Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005;109:583-588.
23. 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 2006;240:15-19.
24. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y: Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:249-251.
25. Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T: Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol 2003;106:374-382.
26. Imamura T, Hirono N, Hashimoto M, Shimomura T, Tanimukai S, Kazui H, Hanihara T, Mori E: Clinical diagnosis of dementia with Lewy bodies in a Japanese dementia registry. Dement Geriatr Cogn Disord 1999;10:210-216.
27. Yamada T, Hattori H, Miura A, Tanabe M, Yamori: Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese population. Psychiatry Clin Neurosci 2001;55:21-25.
28. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, McKeith IG, O'Brien JT: Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643-649.
29. 99mTc-ECD SPET for diagnosis of dementia with Lewy bodies. Eur J Nucl Med 2002;29:1342-1348.
30. Hashimoto M, Kitagaki H, Imamura T, Hirono N, Shimomura T, Kazui H, Tanimukai S, Hanihara T, Mori E: Medial temporal and whole-brain atrophy in dementia with Lewy bodies. A volumetric MRI study. Neurology 1998;51:357-362.
31. Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT: MRI volumetric study of dementia with Lewy bodies. A comparison with AD and vascular dementia. Neurology 2000;54:1304-1309.
32. Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, McKeith IG, Scheltens P, Barkhof F, O'Brien JT: Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002;17:618-630.
33. Hanyu H, Shimizu S, Tanaka Y, Kanetaka H, Iwamoto T, Abe K: Differences in magnetization transfer ratios of the hippocampus between dementia with Lewy bodies and Alzheimer's disease. Neurosci Lett 2005;380:166-169.
34. Waker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CLE: Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-140.
35. O'Brien JT, Colloby S, Fenwick J, Williams D, Firbank M, Burn D, Aarsland D, McKeith IG: Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925.
36. 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. Neuroimage 2004;23:956-966.
37. McKeith IG, Dickson DW, Lowe J, Emere M, O'Brien JT, Feldman H, Commings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenney RA, Korczyn A, Kosaka K, Lee VMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Landinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M: Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005;65:1863-1872.